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Abstract
Background/Aims: The voltage-gated potassium channel KV11.1 has been originally cloned 
from the brain and is expressed in a variety of tissues. The role of phosphorylation for channel 
function is a matter of debate. In this study, we aimed to elucidate the extent and role of 
protein kinase D mediated phosphorylation. Methods: We employed mass spectrometry, 
whole-cell patch clamp electrophysiology, confocal microscopy, site-directed mutagenesis, 
and western blotting. Results: Using brain tissue from rat and mouse, we mapped several 
phosphorylated KV11.1 residues by LC-MS mass spectrometry and identified protein kinase 
D (PKD1) as possible regulatory kinase. Co-expression of KV11.1 with PKD1 reduced current 
amplitudes without altering protein levels or surface expression of the channel. Based 
on LC-MS results from in vivo and HEK293 cell experiments we chose four KV11.1 mutant 
candidates for further functional analysis. Ablation of the putative PKD phosphorylation site 
in the mutant S284A increased the maximal current indicating S284 as a main PKD target in 
KV11.1. Conclusions: Our data might help mitigating a long-standing controversy in the field 
regarding PKC regulation of KV11.1. We propose that PKD1 mediates the PKC effects on KV11.1 
and we found that PKD targets S284 in the N-terminus of the channel.
IntroductionThe potassium channel KV11.1 is encoded by KCNH2 and also known as human-ether-a-go-go related gene type 1 (hERG). The tetrameric channel protein is expressed in a variety 
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of tissues including brain, heart, pancreas, vasculature, and a number of tumors [1]. It is best known for its role in the heart, where it is the molecular correlate of the rapid delayed rectifying current IKr [2, 3]. Mutations in the KCNH2 gene are associated with several cardiac 
arrhythmias such as Long QT and Short QT syndromes and atrial fibrillation [1, 2, 4].Several posttranscriptional and posttranslational mechanisms have been described to 
finetune expression levels and/or biophysical parameters of KV11.1 [5–7]. Protein kinase A (PKA) phosphorylates KV11.1 directly at four consensus sites in vitro [8, 9]. Protein kinase C (PKC) effects have been investigated in different expression systems and experimental models (reviewed in [1]). Despite numerous studies, it is still unresolved whether PKC 
directly phosphorylates the channel protein. Identification of 18 consensus sites by prediction algorithms and individual ablation of these sites did not provide any evidence for a direct phosphorylation at these sites [10, 11]. Cockerill et al. provided evidence for a role of the channel’s N-terminus for PKC mediated phosphorylation [11]. It has been suggested that an atypical PKC phosphorylation site might be involved in the PKC effects [1, 11].Noteworthy, multiple lines of evidence indicate that PKC activity is indispensable for 
activation of protein kinase D (PKD). Especially, the novel PKCs Ɛ and h give robust activation 
of PKD [12] but also classical PKCα can activate PKD [13]. PKD is expressed in a variety of 
tissues and its function has been implicated in health and disease (reviewed in [14–16]). 
Several studies found that a variety of stimuli induce PKD activation through the α-adrenergic pathway, and in many cases this could be attenuated by PKC inhibition [17–19]. Here, we hypothesized that PKC effects on KV11.1 are mediated through PKD1. 
Materials and Methods
Protein biochemistry
Preparation of brain samples. All procedures involving animals conformed to Danish animal welfare 
regulations. Briefly, mouse or rat brain was cut in smaller pieces, homogenized in buffer [in mM: 50 Tris/HCl 
pH 7.4, 2.5 EGTA, 5 EDTA, 10 NaCl, 10 KCl, 0.5 pefabloc, 0.1 NaF, and 320 sucrose with a protease inhibitor 
cocktail (in µg/mL: 2 aprotinin, 1 leupeptin, 2 antipain, 10 benzamidine, and one tablet of phosSTOP/10 mL)] and centrifuged. The supernatant was retained, centrifuged again, and pellets were resuspendend in 2.5 mL homogenizing buffer for every gram of brain.
Preparation of HEK293 cell samples. HEK293 cells were transfected with KV11.1 alone or co-expressed 
with PKD1. For mass spectrometry the cells were grown in a special media, immunoprecipitated and 
digested to peptides. For lysates cells were harvested in solubilization buffer without detergent [in mM: 50 
Tris pH 8.5, 150 NaCl, 5 EDTA] and supplemented with 8 µM leupeptin, 0.4 mM pefabloc and one tablet of 
phosSTOP pr. 10 mL, centrifuged (2 min, 100 x g) and incubated with solubilization buffer containing 1% 
NP-40 on a spinning wheel for 3 hours. Samples were centrifuged at >10.000 x g for 10 min and supernatants were aliquoted, frozen in liquid nitrogen and stored until further use.
Sample preparation for mass spectrometry.  Sample lysates were precleared with Protein G-dynabeads (Invitrogen). Then primary antibody (2 μg/1 mg total protein in the sample) was added followed by 
overnight incubation. After addition of dynabeads in lysis buffer [in mM: 50 Tris/HCl, pH 8.5, 5 EDTA, 150 
NaCl] containing 1% NP-40, 8 µM leupeptin (Sigma), 0.4 mM pefabloc (Sigma), one tablet of phosSTOP pr. 10 mL (Roche) and incubation for 2 h, multiple wash steps were performed. At the end beads were resuspended in Laemmli buffer (containing 100 mM DTT) and incubated for 3 min at 70°C.
Mass spectrometry. Immunoprecipitated proteins were separated by SDS-PAGE, fixed, stained, bands excised and proteins proteolytically cleaved to peptides as previously described [20, 21]. Peptide separation was performed by reversed-phase C18 HPLC on an Easy nLC system (Thermo Fisher Scientific). The effluent 
from the HPLC was directly electrosprayed into an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher 
Scientific, Slangerup, Denmark) through a nano-spray ion source. The peptide mixture was analyzed by full-scan MS spectra (m/z 300-2000, resolution 30, 000) in the Orbitrap analyzer. For every full-scan the 
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most intense peptide ions were sequentially isolated, fragmented by higher energy collisional dissociation 
(HCD), and fragments were recorded by the Orbitrap mass analyzer. The acquired data was processed by MaxQuant (version 1.1.1.25) (Max-Planck Institute of Biochemistry, Department of Proteomics and Signal Transduction, Munich, Germany).
Patch-clamp electrophysiology
Recordings. All recordings of transiently transfected HEK293 cells were performed in the whole-cell 
patch clamp configuration using an EPC9 patch clamp amplifier (HEKA Elektronik, Lambrecht, Germany). Data acquisition was done with the Pulse software (HEKA Electronik). The series resistance recorded in 
the whole cell configuration was kept below 10 MΩ and compensated (80%). The extracellular solution 
contained [in mM: 140 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, and 10 HEPES, pH=7.4]. The intracellular solution 
contained [in mM: 110 KCl, 10 EGTA, 5.17 CaCl2, 1.42 MgCl2, 4 K2ATP, and 10 HEPES, pH=7.2]
Protocols.  Current–voltage (I/V) relations were obtained from the step-protocol by plotting the outward current at the end of the 1-second test pulse as a function of the test potential. The voltage-dependence of 
activation was determined by fitting the amplitude of peak tail currents versus test potential to a two-state 
Boltzmann distribution of the form I(V) = 1/(1+exp [(V½ − V)/a]), where V½ = potential for half-maximal 
activation, and a = slope factor. Other kinetic parametres were analysed as described in detail  (for all online 
suppl. material, see www.karger.com/doi/10.1159/000491007) in the Supplementary Methods.
Data analysis. Data analysis was performed using Excel (Microsoft), Igor Pro 4.04 (Wavemetrics, 
OR, USA) and Prism 4 (GraphPad Software, CA, USA). All values are given as mean ± SEM. The number of independent experiments is indicated by n. Statistical comparisons of results were performed using one-
way analysis of variance (ANOVA) or two-way ANOVA. Following ANOVA, Bonferroni’s method of multiple 
comparisons was used to identify significant differences between means. A value of P <0.05 was considered 
statistically significant.
Antibodies
Primary antibodies: anti-KV11.1, APC-062 (Alomone, Jerusalem, Israel, 1:500); anti-PKD1, 
H00005587-A01 (Abnova, Roskilde, Denmark, 1:500); anti-β-tubulin, MAB3408 (Millipore, Hellerup, 
Denmark, 1:4000).
Secondary antibodies: For western blot analyses; peroxidase conjugated affinipure F(ab)fragment 
donkey anti-rabbit and anti-mouse (Jackson ImmunoResearch, Suffolk, UK), donkey anti-mouse 680RD, 
926-68072 (LI-COR Biosciences, Copenhagen, Denmark); goat anti-rabbit 800CW, 926-32211 (LI-COR 
Biosciences). For confocal imaging; Alexa Fluor®488-conjugated donkey anti-rabbit IgG (1:200), Alexa 
Fluor®568-conjugated donkey anti-mouse IgG (1:200). Alexa®Fluor 647 Phalloidin (1:200) was used to 
stain actin filaments and DAPI (1:300) was used to stain the nucleus. Secondary antibodies were purchased from Invitrogen (Glostrup, Denmark).
Molecular biologyPoint mutations in KV11.1 (GenBank Acc. No. NM_000238) were introduced by standard site-directed 
mutagenesis. All constructs were verified by complete DNA sequencing of the cDNA insert (Macrogen 
Inc., Seoul, Rep. of Korea). Human protein kinase D1 (PKD1, NM_002742) expression plasmid was kindly 
provided by Dr. A. Hausser (University of Stuttgart, Germany) [22].
Results
KV11.1 is phosphorylated in vivo at a  residue matching a consensus recognition site for 
PKD
First, we mapped the in vivo phosphorylation sites of KV11.1 using tissue samples, where KV11.1 channels from both mouse and rat brain tissue were purified by immunoprecipitations 
and submitted to analysis by LC-MS/MS mass spectrometry. Our analysis led to identification 
of 14 in-vivo phosphorylation sites (Table 1). In Table 1 we assigned the identified residues 
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from mouse and rat to the nomenclature of the human KV11.1 residues by alignment of mouse, rat, and human sequences (see 
online suppl. material, Suppl. Fig. S1). Our 
data confirmed phosphorylation at residue S283 which had been reported as a site for PKA-mediated phosphorylation previously 
[9]. None of the identified residues were 
PKC consensus sites; however, S284 was a strong candidate for PKD phosphorylation.
Co-expression of PKD1 reduces KV11.1
current densities
We assessed a possible role of PKD1 by employing whole-cell patch clamp 
recordings. We transiently transfected HEK293 cells with KV11.1 alone or co-
expressed with PKD1 cDNA (Fig. 1). To investigate the potassium currents, we applied a standard step protocol with 1 s test 
pulses ranging from -100 to +60 mV in 10 mV 
increments. Fig. 1A shows representative current recordings of KV11.1 and KV11.1 
+ PKD1. As expected, the current/voltage relationship (IV curve) resulted in the characteristic bell-shape due to inactivation 
of the channel [3]. Of note, a high degree of cell to cell variability of current levels was seen in line with literature [23]. The maximum outward current amplitude was normalized to the cell capacitance and used to construct the current-voltage (I-V) relationship of KV11.1 (n=7) and KV11.1 co-expressed with PKD1 (n=7) (Fig. 1B). 
The maximum outward current amplitude at +20 mV for KV11.1 was 29.5±9.5 pA/pF and 
significantly reduced by 56.2 % upon co-expression with PKD1 (12.9±1.7 pA/pF, P=0.018). 
Table 1. Phosphosites in mouse and rat tissue and 
HEK293 cells determined by LC-MS/MS. Numbering based on human sequence (in italics corresponding residue in rat or mouse, respectively). Best motif is predicted by MaxQuant [38]. tissue HEK293 best motif rat brain mouse brain   - S140  ERK/MAPK S239 (S241) S239 (S241)  ERK/MAPK S250 (S252) -  CDK1 
- - S263  
- - S266  S283 (S285) -  PKA S284 (S286) - S284 PKD S304 (S306) -  CamKII T319 (T321) - T319 NEK6  S320 (S322) S320  - S322 (S324) S322 CK1 - S351 (S353)  Proline-directed - T353 (T355) T353  
- S871 (S873)  ERK/MAPK 
- S874 (S876)  CK1 S969 (S971) -   
 
Fig. 1. Co-expression of PKD1 reduces KV11.1 current amplitudes. A. Representative current recordings of KV11.1 and KV11.1+PKD1 from transiently transfected HEK293 cells. The insert depicts the voltage clamp protocol. B. Currents measured at the end of each step were used to construct the current-voltage (IV) relationship. C. Tail currents and D. normalized tail currents measured 
at -60 mV. The solid lines correspond to 
the fitted Boltzmann functions. KV11.1 (n=7) and KV11.11+PKD (n=7). *P<0.05, 
**P<0.01, ***<0.001.
Figure 1 
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The tail current amplitude was also reduced 
by PKD1 co-expression (Fig. 1C). KV11.1 current reduction has earlier been assigned to a shift of the voltage-dependent activation to 
more depolarized potentials [24]. Therefore, 
the normalized peak tail currents were fitted to a Boltzmann function to determine the V½ values of voltage-dependent activation. No difference of the voltage-dependent activation 
upon co-expression of PKD1 (Fig. 1D, Table 2) was observed. Deactivation, inactivation and recovery from inactivation properties (Table 2) were unchanged.
PKD1 co-expression does not alter protein 
levels or surface expression of Kv11.1
We assessed whether PKD1 co-expression would affect KV11.1 protein expression 
or subcellular localization. Western blot experiments revealed that there was no change in protein levels (see online suppl. 
material, Suppl. Fig. S2). PKD1 did not alter the localization of KV11.1 in HEK293 cells, and KV11.1 and PKD1 were both localized in the plasma membrane as assessed by confocal microscopy (see online suppl. material, Suppl. 
Fig. S3). Attempts to test a possible direct interaction between KV11.1 channel and PKD1 by co-immunoprecipitation remained unsuccessful (data not shown).
PKD1 co-expression leads to KV11.1 phosphorylation in HEK293 cells
To analyse whether S284 and other residues would be phosphorylated by PKD1, we immunoprecipitated KV11.1 channels co-expressed with PKD1 in HEK293 cells to map 
the phosphorylation sites by mass spectrometry. We identified seven residues that were phosphorylated upon co-expression with PKD1. This indicated that PKD1 could affect KV11.1 phosphorylation in a heterologous expression system by direct phosphorylation of 
several residues. MS/MS spectra for all identified sites with evidence for site localization are 
provided (see online suppl. material) in Suppl. Fig. S4-9. A few residues did stand out from 
the data; Residue S284 appeared to be phosphorylated in HEK293 cells co-expressed with 
PKD1. In addition, it was identified in vivo and motif-wise PKD1 was the most likely kinase 
to phosphorylate this site, making S284 our prime candidate for PKD1 phosphorylation. Also 
amino acids S263 and S266 were phosphorylated. S266 was identified to be phosphorylated 
by itself, whereas S263 was only identified in peptides where S266 was also phosphorylated and we decided to address their combined effect in the subsequent functional analysis. S322 was phosphorylated and found in a cluster together with S318, T319, and S320. Three of the four were found phosphorylated in vivo. We chose to address the combined effects of the 
four residues in the cluster. Finally, residue T353 appeared to be phosphorylated in HEK293 cells and in vivo.
Functional analysis of KV11.1 mutants supports S284 as possible PKD target
We sought to address the functional impact of the selected amino acids after ablation of the serine residues to alanine (A) hereby mimicking the dephosphorylated state. To this end, we generated four KV11.1 mutants (KV11.1-S284A, KV11.1-S263/S266A, KV11.1-S318/
Table 2. Effect of PKD1 co-expression on the biophysical properties of KV11.1. *P<0.05
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T319/S320/S322A, and KV11.1-T353A). We expressed the mutant channels in HEK293 and analysed biophysical parameters by patch-clamp electrophysiology.KV11.1-S284A displayed a significantly higher maximum outward current amplitude than wild-type KV11.1 at +20 mV; 
S284A: 58.2±6.9 (n=11), WT: 29.9±3.5 pA/
pF (n=8, P<0.001) respectively; (Fig. 2A,B) indicating that this residue mediates at least some of the PKD1 phosphorylation effect on the channel. Also the tail current amplitude 
was significantly higher for the mutant (Fig. 
2C). We did not observe any significant shift in the voltage-dependent activation for KV11.1-S284A compared with wild-type 
(Fig. 2D, Table 3). The slow time constant of 
deactivation was significantly faster at -60 
and -50 mV for the S284A mutant compared 
to wild-type. Other voltage-dependent and kinetic parameters were unaffected by the 
alanine mutation (Table 3). We analysed 
protein levels of S284A by western blotting experiments and found that expression levels were similar to wild-type channels 
(see online suppl. material, Suppl. Fig. S2). KV11.1-S263/S266A, KV11.1-S318/T319/
S320/S322A, and KV11.1-T353A behaved similarly to wild-type channels (see online suppl. material, Suppl. Table S1).
DiscussionKV11.1 is an important potassium channel which is manifested in its association with inherited and acquired cardiac arrhythmia where even mild changes of the conducted current 
Fig. 2. Ablation of phosphorylation site 
S284 increases KV11.1 mediated currents. A. Representative current recordings of KV11.1-WT and KV11.1-S284A from transiently transfected HEK293 cells. The insert shows the voltage clamp protocol. B. Currents measured at the end of each step were used to construct the current-voltage (IV) relationship. C. Tail currents and D. 
normalized tail currents measured at -60 
mV. The solid lines correspond to the fitted Boltzmann functions. KV11.1 (n=8) and KV11.1-S284A (n=11). *P<0.05, ***P<0.001.
Figure 2  
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Table 3. Effect of S284 ablation on biophysical 
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may have deleterious effects. The current conducted by KV11.1 is regulated by a number 
of physiological stimuli mediated by G-protein coupled receptors, e.g. α- and β-adrenergic, muscarinic, and angiotensin II receptors [11, 25–29]. Hence, understanding the molecular basis of the regulation is crucial for elucidating disease mechanisms [1, 30]. Here, we provide evidence for involvement of protein kinase D based on in vivo and in vitro mass-spectrometry 
findings together with functional analysis of wild-type and mutant KV11.1 channels.LC-MS mass spectrometry revealed several phosphorylated residues in vivo and suggested PKD as a strong candidate. Co-expression of KV11.1 with PKD1 reduced current 
amplitudes; however, we were unable to identify significant changes in kinetic parameters that could explain the decrease in Imax. Protein levels were unaffected. Due to the lack of 
specific pharmacological tools, i.e. specific activators or blockers of PKD1 which would allow 
for an assessment of PKD1 effects independent of PKC in patch-clamp recordings [14], we instead chose four candidate KV11.1 mutants for further functional analysis based on the results obtained from HEK293 cell experiments and in vivo data. Ablation of the putative 
PKD phosphorylation site in the mutant S284A increased the maximal current.
Our data might help mitigating a long-standing controversy in the field regarding PKC regulation of the channel. Most studies have investigated the acute effects of different pathways upstream of PKC activation with variable results ranging from reports indicating that neither PKC nor PKA are involved [31], that PKA and PKC show composite and partial effects with complex cross-talk [32], or that either convential PKC (cPKC) [10] or novel 
PKC (nPKC) [25] are exclusively involved. Other pivotal points of discussion have been whether PKC phosphorylates the channel directly [10, 11, 27] and whether PKC mediated phosphorylation increases [32] or decreases current KV11.1 (or IKr)  amplitudes [10, 11, 24, 
26, 27]. However, the majority of studies found a positive shift in the voltage-dependence of activation and an acceleration of deactivation, with different levels of reduction of the KV11.1 current amplitude (e.g [10, 11, 27, 33].)
Our results support the notion that PKC mediated functional effects are independent 
of the previously suggested consensus sites [10]. They also confirm a role of the N-terminal 
part of the protein as proposed by other studies [11, 34]. Cockerill and coworkers found 
that residues 2-354 of the KV11.1 N-terminus are critical for both cPKC phosphorylation and 
functional modulation of the channel [11]. Of note, both cPKC [13] and nPKC [12] have been 
reported to activate PKD1. While we cannot rule out that PKC exerts a variety of direct and indirect effects, we propose that PKD1 is a new player, either activated independently or 
downstream of PKC, targeting S284 in the N-terminus of the channel.Recent attempts to resolve the identity of the involved PKC isoform by using inhibitory peptidomimmetics indicated a predominant role of PKCε, with minor contributions of PKCβ, PKCα, and PKCη [35]. Interestingly, Haworth and coworkers reported that in adult 
cardiomyocytes PKCε is the predominant activator of PKD and this activation was somewhat counteracted by PKA activation indicating a crosstalk between the two kinase pathways [18]. 
This crosstalk might mainly be a PKC effect on the cAMP level [36, 37], but the molecular mechanism behind this is currently unclear. Therefore, we did not investigate the candidates that are already known to be phosphorylated by PKA.
Conclusion
Our data indicate that PKD1 contributes to KV11.1 regulation by targeting S284 in the N-terminus of the channel. This pathway could therefore present an explanation to years of divergent results regarding the regulation of IKr or KV11.1 by protein kinases.
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